Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management (The TRIUMPH Study)
Tofacitinib is an effective rescue therapy in hospitalized patients with steroid-refractory ASUC. Randomized controlled trials are warranted to compare JAK inhibitors with other rescue therapies, including infliximab in steroid-refractory ASUC (Clinicaltrials.gov: NCT04925973).
Authors
- Hasan Hamam (ORCID: https://orcid.org/0009-0000-6999-3125)
- Talat Bessissow (ORCID: https://orcid.org/0000-0003-2610-1910)
- Neeraj Narula (ORCID: https://orcid.org/0000-0002-1536-8436)
- Brian Bressler (ORCID: https://orcid.org/0000-0003-4740-8209)
- Farhad Peerani (ORCID: https://orcid.org/0000-0003-1865-3192)
- John Marshall (ORCID: https://orcid.org/0000-0002-1216-5457)
- Cara Pray (ORCID: https://orcid.org/0009-0009-9244-8235)
- Tawnya Hansen
- Jane Castelli
- M Schmit
- Arathi Arun
Institutions
- Alberta Hospital Edmonton (CA)
- McMaster University Medical Centre (CA)
- McGill University Health Centre (CA)
- Health Sciences Centre (CA)
- University of Alberta Hospital (CA)
- University of Manitoba (CA)
Publication Details
- Journal
- Crohn s & Colitis 360
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1093/crocol/otaf013
- Citations
- 6
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 3.30
Funders
- Pfizer
- Pfizer Canada